- Home
- ARQT vs BCSF Comparison
ARQT vs BCSF Comparison
Compare ARQT & BCSF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARQT
- BCSF
- Stock Information
- Founded
- ARQT 2016
- BCSF 2015
- Country
- ARQT United States
- BCSF United States
- Employees
- ARQT N/A
- BCSF N/A
- Industry
- ARQT Biotechnology: Pharmaceutical Preparations
- BCSF Finance/Investors Services
- Sector
- ARQT Health Care
- BCSF Finance
- Exchange
- ARQT Nasdaq
- BCSF Nasdaq
- Market Cap
- ARQT 1.1B
- BCSF 1.2B
- IPO Year
- ARQT 2020
- BCSF 2018
- Fundamental
- Price
- ARQT $13.02
- BCSF $18.63
- Analyst Decision
- ARQT Strong Buy
- BCSF Hold
- Analyst Count
- ARQT 6
- BCSF 4
- Target Price
- ARQT $17.00
- BCSF $17.00
- AVG Volume (30 Days)
- ARQT 2.3M
- BCSF 195.1K
- Earning Date
- ARQT 02-25-2025
- BCSF 02-27-2025
- Dividend Yield
- ARQT N/A
- BCSF 9.70%
- EPS Growth
- ARQT N/A
- BCSF N/A
- EPS
- ARQT N/A
- BCSF 1.99
- Revenue
- ARQT $138,708,000.00
- BCSF $294,257,000.00
- Revenue This Year
- ARQT $217.37
- BCSF N/A
- Revenue Next Year
- ARQT $55.64
- BCSF N/A
- P/E Ratio
- ARQT N/A
- BCSF $9.33
- Revenue Growth
- ARQT 182.84
- BCSF 3.17
- 52 Week Low
- ARQT $6.99
- BCSF $15.27
- 52 Week High
- ARQT $16.20
- BCSF $18.77
- Technical
- Relative Strength Index (RSI)
- ARQT 50.16
- BCSF 74.13
- Support Level
- ARQT $11.13
- BCSF $17.71
- Resistance Level
- ARQT $13.62
- BCSF $18.23
- Average True Range (ATR)
- ARQT 1.04
- BCSF 0.25
- MACD
- ARQT 0.08
- BCSF 0.04
- Stochastic Oscillator
- ARQT 67.26
- BCSF 86.32
About ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's lead product candidate ZORYVE roflumilast cream, has successfully completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.
About BCSF Bain Capital Specialty Finance Inc.
Bain Capital Specialty Finance Inc is an externally managed, closed-end, non-diversified management investment company. The company's objective is to provide risk-adjusted returns and current income to investors by investing predominantly in middle-market companies with between $10.0 million and $150.0 million in annual EBITDA. Its portfolio of investments includes, First Lien Senior Secured Loan, Preferred Equity, Equity Interest, and Second Lien Senior Secured Loan among others.